Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers


  Free Subscription

Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 38 articles:
HTML format

Single Articles

    September 2023
  1. LIU R, Staruschenko A
    Matrix Metalloproteinase 2 is crucial for hypertension- and hyperglycemia-induced kidney injury independent of blood pressure.
    J Cardiovasc Pharmacol. 2023 Sep 28. doi: 10.1097/FJC.0000000000001488.

  2. BROCKMOLLER J, Ivanoski S, Hundack L, Blohm JH, et al
    Clinical and hemodynamic improvement in pulmonary hypertension after switching to sacubitril/valsartan in heart failure patients with preserved ejection fraction.
    J Cardiovasc Pharmacol. 2023 Sep 1. doi: 10.1097/FJC.0000000000001477.
    PubMed     Abstract available

    August 2023
  3. HIRATA T, Fan F, Fan L, Amin G, et al
    Knockout of Matrix Metalloproteinase 2 Opposes Hypertension- and Diabetes-Induced Nephropathy.
    J Cardiovasc Pharmacol. 2023 Aug 25. doi: 10.1097/FJC.0000000000001473.
    PubMed     Abstract available

  4. CERON CS, Luizon MR, Palei AC
    The Potential Role of Visfatin in Mediating Vascular Dysfunction and Hypertension.
    J Cardiovasc Pharmacol. 2023 Aug 9. doi: 10.1097/FJC.0000000000001457.

  5. KAPLAN A, Lakkis B, El-Samadi L, Karaayvaz EB, et al
    Cooling Down Inflammation in the Cardiovascular System via the Nicotinic Acetylcholine Receptor.
    J Cardiovasc Pharmacol. 2023 Aug 4. doi: 10.1097/FJC.0000000000001455.
    PubMed     Abstract available

    October 2022
  6. KANG L, Liu X, Li Z, Li X, et al
    Sildenafil improves pulmonary vascular remodeling in a rat model of persistent pulmonary hypertension of the newborn.
    J Cardiovasc Pharmacol. 2022 Oct 1. pii: 00005344-990000000-00118.
    PubMed     Abstract available

  7. GUHA A, Gong Y, DeRemer D, Owusu-Guha J, et al
    Cardiometabolic Consequences of Targeted Anticancer Therapies.
    J Cardiovasc Pharmacol. 2022;80:515-521.
    PubMed     Abstract available

    September 2022
  8. SWAMI VETHA BS, Byrum R, Peele K, Diz D, et al
    Functional Significance of Angiotensin Receptor Type 2 in the Neuroplasticity of Autonomic Ganglia in (mRen2)27 Transgenic Hypertensive Rats.
    J Cardiovasc Pharmacol. 2022 Sep 16. pii: 00005344-990000000-00116.
    PubMed     Abstract available

  9. Sacubitril/Valsartan Improves Sexual Function and Fibrosis of the Clitoral and Vaginal Tissues in Female Spontaneously Hypertensive Rats: Erratum.
    J Cardiovasc Pharmacol. 2022;80:489.

    August 2022
  10. CHUQUIN D, Abbate A, Bottinor W
    Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment.
    J Cardiovasc Pharmacol. 2022 Aug 25. pii: 00005344-990000000-00110.
    PubMed     Abstract available

  11. YANG S, Shen W, Zhang HZ, Wang CX, et al
    Efficacy and Safety of Finerenone for Prevention of Cardiovascular Events in Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00107.
    PubMed     Abstract available

  12. D'SOUZA MS, Luu AN, Guisinger TC, Seeley SL, et al
    Regulator of G-Protein Signaling 5 Protein Deficiency Differentially Influences Blood Pressure, Vascular and Behavioral Effects in Aged Male Mice.
    J Cardiovasc Pharmacol. 2022;80:305-313.
    PubMed     Abstract available

    July 2022
  13. IMAM SS, El-Farrash RA, Taha AS, Saleh GA, et al
    Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial.
    J Cardiovasc Pharmacol. 2022 Jul 12. pii: 00005344-990000000-00081.
    PubMed     Abstract available

    May 2022
  14. CAI H, Fan S, Cai L, Zhu L, et al
    Dihydroartemisinin attenuates hypoxia-induced pulmonary hypertension through the ELAVL2/miR-503/PI3K/AKT axis.
    J Cardiovasc Pharmacol. 2022 May 5. pii: 00005344-990000000-00028.
    PubMed     Abstract available

    April 2022
  15. CHENG L, Maboh RN, Wang H, Mao GW, et al
    Naoxintong capsule activates the Nrf2/HO-1 signaling pathway and suppresses the p38alpha signaling pathway via estrogen receptors to ameliorate heart remodeling in female mice with postmenopausal hypertension.
    J Cardiovasc Pharmacol. 2022 Apr 29. pii: 00005344-990000000-00034.
    PubMed     Abstract available

  16. BAO M, Song Y, Wu S, Li J, et al
    The influence of hypersensitive C-reactive protein on the effect of continuous antihypertensive pharmacological therapy.
    J Cardiovasc Pharmacol. 2022 Apr 5. pii: 00005344-990000000-00017.
    PubMed     Abstract available

  17. CHAN TH, Tsoi MF, Yung Cheung BM
    Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study.
    J Cardiovasc Pharmacol. 2022;79:577-582.
    PubMed     Abstract available

    March 2022
  18. ZHUANG C, Yi G, Wang W, Sun R, et al
    Sacubitril/Valsartan Improves Sexual Function and Fibrosis of the Clitoral and Vaginal Tissues in Female Spontaneously Hypertensive Rats.
    J Cardiovasc Pharmacol. 2022 Mar 8. pii: 00005344-990000000-00003.
    PubMed     Abstract available

  19. JOB R, Abdul Qader M, Torres P, Al Abbasi B, et al
    Renin-Angiotensin System Blocker in COVID-19. A Single Center Study.
    J Cardiovasc Pharmacol. 2022;79:311-314.
    PubMed     Abstract available

  20. HAN H, Dou J, Hou Q, Wang H, et al
    Role of Circadian Rhythm and Impact of Circadian Rhythm Disturbance on the Metabolism and Disease.
    J Cardiovasc Pharmacol. 2022;79:254-263.
    PubMed     Abstract available

    November 2021
  21. TEMIZ-RESITOGLU M, Guden DS, Senol SP, Vezir O, et al
    Pharmacological inhibition of mTOR attenuates DOCA-salt-induced hypertension and related pathophysiology: regulation of oxidative stress, inflammation and cardiovascular hypertrophy in male rats.
    J Cardiovasc Pharmacol. 2021 Nov 23. pii: 00005344-900000000-98105.
    PubMed     Abstract available

    October 2021
  22. ALVES QL, Vieira da Silva Santos P, Santos WA, Dantas Damasceno SC, et al
    Unraveling the cardiac effects induced by carvacrol in spontaneously hypertensive rats: Involvement of TRPM4 and TRPM7 channels.
    J Cardiovasc Pharmacol. 2021 Oct 28. pii: 00005344-900000000-98123.
    PubMed     Abstract available

  23. ZHU T, Wang X, Zheng Z, Quan J, et al
    ZIP12 Contributes to Hypoxic Pulmonary Hypertension by Driving Phenotypic Switching of Pulmonary Artery Smooth Muscle Cells.
    J Cardiovasc Pharmacol. 2021 Oct 21. pii: 00005344-900000000-98129.
    PubMed     Abstract available

  24. ABDELMONEM M, Ebada MA, Diab S, Ahmed MM, et al
    Efficacy of Hibiscus Sabdariffa on Reducing Blood Pressure in Patients with Mild to Moderate Hypertension: A Systematic Review and Meta-Analysis of published randomized controlled trials.
    J Cardiovasc Pharmacol. 2021 Oct 20. pii: 00005344-900000000-98127.
    PubMed     Abstract available

  25. ADIE SK, Abdul-Aziz AA, Ketcham SW, Moles VM, et al
    Considerations for inotrope and vasopressor use in critically ill patients with pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2021 Oct 6. pii: 00005344-900000000-98139.
    PubMed     Abstract available

    August 2021
  26. LUO S, Kan J, Zhang J, Ye P, et al
    Bioactive Compounds From Coptidis Rhizoma Alleviate Pulmonary Arterial Hypertension by Inhibiting Pulmonary Artery Smooth Muscle Cells' Proliferation and Migration.
    J Cardiovasc Pharmacol. 2021;78:253-262.
    PubMed     Abstract available

    July 2021
  27. PENG M, He J, Xue Y, Yang X, et al
    The role of hypertension on the severity of COVID-19: a review.
    J Cardiovasc Pharmacol. 2021 Jul 22. pii: 00005344-900000000-98170.
    PubMed     Abstract available

  28. KRYSIAK R, Basiak M, Okopien B
    Impact of lisinopril on cardiometabolic risk factors in men with hypertension and early-onset androgenetic alopecia: a pilot study.
    J Cardiovasc Pharmacol. 2021 Jul 20. pii: 00005344-900000000-98169.
    PubMed     Abstract available

  29. WANG Y, Wang JW, Wang Y, Yang B, et al
    Monitoring Antihypertensive Medication Adherence by LC-MS/MS: Method Establishment and Clinical Application.
    J Cardiovasc Pharmacol. 2021 Jul 9. pii: 00005344-900000000-98173.
    PubMed     Abstract available

    June 2021
  30. HAMMOUD S, Kurdi M, van den Bemt BJ
    Impact of Fasting on Cardiovascular Outcomes in Patients with Hypertension.
    J Cardiovasc Pharmacol. 2021 Jun 29. pii: 00005344-900000000-98181.
    PubMed     Abstract available

  31. WATSON K, Kukin A, Wasik AK, Shulenberger CE, et al
    Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2021;77:685-698.
    PubMed     Abstract available

    May 2021
  32. YANG S, Zhang H, Yang P, Wang C, et al
    Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021;77:650-659.
    PubMed     Abstract available

  33. ZOUEIN FA, Altara R, Massoud GP, Booz GW, et al
    The Angiotensin II Type 1(AT1) Receptor and Cardiac Hypertrophy: Did We Have It Wrong All Along?
    J Cardiovasc Pharmacol. 2021;77:531-535.
    PubMed     Abstract available

    April 2021
  34. MCCOY EK, Lisenby KM
    Aprocitentan (a dual endothelin receptor antagonist) for Treatment-Resistant Hypertension.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98239.
    PubMed     Abstract available

  35. YAMAGATA K, Yamori Y
    Altered properties of neurons and astrocytes and the effects of food components in stroke-prone spontaneously hypertensive rats.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98237.
    PubMed     Abstract available

  36. GILEWSKI W, Banach J, Rogowicz D, Wolowiec L, et al
    Treatment of hypertension due to immunosuppressive therapy after solid organ transplantation - pharmacological approach.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98236.
    PubMed     Abstract available

  37. MIOTTO DS, Duchatsch F, Macedo AG, Ruiz TFR, et al
    Perindopril Reduces Arterial Pressure and Does Not Inhibit Exercise-Induced Angiogenesis in Spontaneously Hypertensive Rats.
    J Cardiovasc Pharmacol. 2021;77:519-528.
    PubMed     Abstract available

    March 2021
  38. RAJABI S, Najafipour H, Farsangi SJ, Joukar S, et al
    Quercetin, Perillyl alcohol and Berberine ameliorate right ventricular disorders in experimental pulmonary arterial hypertension: Effects on miR-204, miR-27a, fibrotic, apoptotic and inflammatory factors.
    J Cardiovasc Pharmacol. 2021 Mar 12. pii: 00005344-900000000-98234.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge.